A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 129 participants.

Also called NCT03619850

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 129 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03619850
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Hungary, Lithuania, Mexico, Poland (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT03619850. Randomized; no masking; primary purpose treatment. Start 2018-08-13 (actual); primary completion 2026-08-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
Condition
Chronic Kidney Disease; Iron Deficiency Anemia
Intervention (Drug)
Ferumoxytol
Intervention (Drug)
Iron sucrose
Lead sponsor
AMAG Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03619850
Content hash
e92f0ba4a7aa3b274d97969e7d61f1c9011d45be066421095ec85a6afbf61805